source
- Attovia Therapeutics raises $289 million in IPO to fund antibody-drug research for skin and inflammatory diseasesAttovia Therapeutics completed an IPO raising $289 million, selling 17 million shares at $17 each and valuing the company at $767 million. Shares will begin trading on Nasdaq under the ticker ATTO.…
- FDA approves Orzeyful, first drug to treat all symptoms of narcolepsy type 1The U.S. Food and Drug Administration announced on August 5, 2026 that it has approved Orzeyful (oveporexton) tablets for adults with narcolepsy type 1. Orzeyful is the first therapy cleared to tr…